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Background: Male infertility is a significant contributor to the need for fertility treatment. Treatment currently
involves correcting any identifiable adverse lifestyle factors in men with suboptimal sperm parameters, and if these
measures are unsuccessful, assisted conception is offered, which can be quite expensive. Raised scrotal temperature
is one of the least studied but easily corrected risk factors for male infertility. In a recent review of the literature,
sperm count, motility and morphology improved with scrotal cooling devices. The devices used to achieve
testicular cooling were, however, not practical for day-to-day use. A potentially more practical device for scrotal
cooling has recently been developed. The Babystart® FertilMate™ Scrotum Cooling Patch is a hydrogel pad which
allows for comfortable application. The aims of this study were to investigate whether exposing the scrotum to
lower temperatures by means of these new patches could improve semen parameters, thereby improving fertility,
and to assess the feasibility of a clinical trial.
Methods/design: This is a randomised controlled trial set in a university teaching hospital in the United Kingdom.
The proposed sample size was 40 men with mild, moderate or severe oligoasthenospermia, of whom 20 would be
randomised to wearing the scrotum cooling patch for 90 days and 20 men would be acting as controls and not
wearing the patches. The primary outcome measure was the change in sperm concentration. Secondary outcome
measures included the change in sperm volume, motility and morphology; endocrine parameters; metabolomic
biomarkers; testicular volume and blood flow. Reasons for dropping out and non-compliance were also going to be
noted and reported.
Discussion: The study started recruiting in October 2011 and as of November 2011 four men had been consented
and were participating in the study. No operational challenges had been encountered at the time of the
submission of this manuscript. Although the study also aimed to evaluate the feasibility of a definitive study, the
change in sperm count after 90 days of wearing the scrotal cooling patches was made the primary outcome
measure because a statistically significant improvement in sperm parameters with the scrotal patches would in itself
be a definitive finding.
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Male infertility is a significant contributor to the need
for fertility treatment in the UK and approximately one-
third of in vitro fertilisation cases are due to male factor
infertility. Sperm integrity is essential for successful con-
ception. Spermatogenesis is a very complex process and
any hindrance to this vital process may result in altered
sperm parameters. Many factors have been associated
with male infertility and impaired spermatogenesis, in-
cluding factors which can be corrected by lifestyle
changes and organic factors. However, in many cases,
the cause is unknown. Lifestyle factors include raised
scrotal temperatures, alcohol, obesity, smoking and free
radicals [1-5]. Organic causes are usually classified as
pre-testicular, testicular and post-testicular. Pre-testicular
causes include endocrine factors which impair spermato-
genesis, such as hypogonadotrophic hypogonadism;
testicular factors include diseases, such as mumps orchi-
tis, trauma or radiation treatment in cancer patients;
post-testicular factors leading to obstruction to the out-
flow of sperm from the epididymis to the penile urethra
can occur after infection and surgery such as vasectomy.
The current approach to treating male infertility
includes correcting any identifiable possible contributory
adverse lifestyle factors, and if unsuccessful, assisted con-
ception by way of intrauterine insemination and in vitro
fertilisation and intracytoplasmic sperm injection.
Assisted conception is, however, invasive and costly.
There is therefore a need to improve the efficacy of non-
invasive and lifestyle treatment options in male
infertility.
Alcohol and smoking are personal choices which can
be corrected with appropriate support and counselling.
Antioxidant supplementation via carnitines and vitamins
C and E can be offered to correct free radicals but
further studies are needed to determine the efficacy and
safety of antioxidant supplementation in the medical
treatment of male infertility. Raised scrotal temperatures
and heat is one of the least studied risk factors for male
infertility, but one that can easily be corrected. Heat has
an adverse effect on spermatogenesis and it is believed
that scrotal temperatures 1 to 2°C below body
temperature would be a natural advantage to normal
sperm morphology [3-5]. In a review of the literature,
sperm count improved in 48% to 66% of the infertile
men studied and six out of eight studies also showed an
improvement in sperm motility, morphology or both
with scrotal cooling, ranging from 28% to 83% [5-12].
The increase in sperm count was noted as early as two
weeks in oligospermic men after treatment initiation but
a statistically significant increase in sperm count was
noticeable from eight weeks onwards. The devices used
to achieve testicular cooling were, however, not practical
for day-to-day use. One device was a curved ice rubbercollar filled with ice cubes that was attached to partici-
pants’ thighs using tapes on either side and was applied
for 30 minutes for 14 consecutive days. A second was a
gel that became solid on freezing. It was wrapped in a
cloth or towel and inserted in the participants’ under-
wear on the anterior aspect of the scrotum every night
for two months. It would thaw within three to four
hours, resulting in a cooling effect. A third device
comprised a cotton suspensory bandage worn for
between 16 to 22 hours for a period that ranged from 8
to 20 weeks, which was held in close contact with the
scrotum and released fluid (water or alcohol) to keep the
scrotum damp. A final example is a device that attached
with a belt to the abdomen and scrotum and released a
continuous air stream to achieve scrotal cooling, which
was applied nocturnally for 12 weeks.
A potentially more user friendly and practical device
for scrotal cooling has recently been developed. The
Babystart® FertilMate™ Scrotum Cooling Patch (Babystart
Limited, Dudley, UK) is a hydrogel pad which is non-
greasy and allows for comfortable application. The scro-
tal cooling patch contains 0.5% w/w natural I-menthol,
which provides the cooling effect. The patch is easily
trimmed and shaped for use on all sizes of scrotum and
comes in a re-sealable bag, with no need for refriger-
ation. The potential benefits with the Babystart® Fertil-
Mate™ Scrotum Cooling Patch include the fact that it is
easily applied, comfortable and maintains the individual’s
dignity and privacy.
There have not been any previously published clinical
trials evaluating the impact of the Babystart® FertilMate™
Scrotum Cooling Patch on male fertility. The aims of this
study were to investigate whether exposing the scrotum
to lower temperatures using this patch could improve
fertility by means of improved semen parameters and to
assess the feasibility of a clinical trial study.Methods
Ethics approval
Local research ethics approval was obtained for this
study from the Nottingham Research Ethics Committee,
East Midlands - Nottingham 1. 11/EM/0163.Study design
The study was designed as a randomised controlled trial
and no stratification will be used.Setting
The study is being carried out in a fertility clinic at a
university teaching hospital in the UK, the Nottingham
University Hospitals NHS Trust, Queens Medical Centre
Campus.
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The proposed sample size is 40 men with mild, moderate
or severe oligoasthenospermia, with 20 men in the
experimental group using the scrotal cooling patch and
20 men in the control group and not receiving the scro-
tal cooling patch. The inclusion criteria include men
presenting to the fertility clinic with mild, moderate or
severe oligoasthenospermia (sperm motility of< 32% and
count of <15 million per millilitre), aged 18 to 45 years
of age. Exclusion criteria include men who have under-
gone a vasectomy or have had any surgery to their geni-
talia, have an allergy to menthol, are aged below 18 or
older than 45 years of age, are unable to consent for
themselves, from vulnerable groups or with a chronic
medical condition, for example diabetes or hypertension.
Recruitment and consent
Prior to each weekly fertility clinic at the Nottingham
University Hospitals, Queen’s Medical Centre campus,
the medical records of all couples to be seen in the clinic
will be reviewed to identify any potentially eligible men
for the study. Men will be approached after their clinic
consultation to be provided with verbal and written
information about the project. If they agree to partici-
pate, written informed consent will be obtained prior to
participation by a competent individual and a signed
document will be retained in their research records. The
initial approach will be from a member of the patient’s
usual care team, which may include the investigator. The
investigator or their nominee, for example, from the
research team or a member of the participant’s usual
care team, will inform the participant of all aspects
pertaining to participation in the study. If needed, the
hospital interpreter and translator services will be avail-
able to assist with discussion of the trial, the participant
information sheets and consent forms, but the consent
forms and information sheets will not be available
printed in other languages.
Potential participants will be told that that entry into
the trial is entirely voluntary and that their treatment
and care will not be affected by their decision. They will
also be told that they can withdraw at any time but
attempts will be made to avoid this occurrence. They will
also have explained to them that, in the event of their
withdrawal, their data collected so far cannot be erased
and we will seek consent to use the data in the final ana-
lyses where appropriate.
Pre-randomisation data
Baseline clinical demographics will be collected from the
participant’s medical records and through a clinical inter-
view, including age, occupation, medical history,
cigarette use, alcohol intake, body mass index and a
working clinical diagnosis. The results of the baselinesemen analysis justifying inclusion into the study will be
recorded in the research proforma and a blood sample
will be collected for endocrine variables, including
testosterone, follicle stimulating hormone and luteinising
hormone. Serum samples will also be stored at −80°C for
metabolomic biomarkers and a three-dimensional ultra-
sound scan of the scrotum will be performed to evaluate
scrotal testicular blood flow, volume and morphology.
Randomisation and blinding
Randomisation will be carried via a web-based
programme. This will be done by accessing the assigned
randomisation status on the web-based program. The
web-based program currently chosen is Randomization.
com [13], which is a free on-line randomisation program
which prints simple lists of random allocations. Alloca-
tion concealment will be achieved by centralised
randomisation. The randomisation program generates a
list of 40 patients in a random sequence and as patients
are recruited they are added to the list in numerical
order of randomisation in line with the predetermined
randomisation sequence.
The researchers performing and analysing data from
the semen samples, endocrine tests, biomarker analysis
and three-dimensional ultrasound scans will be blinded
to the participant grouping.
Interventions
Once randomised, men allocated to the Babystart®
FertilMate™ Scrotum Cooling Patch group will be
provided instructions on its use and asked to apply the
scrotal cooling patch nocturnally for a period of 90 con-
secutive days. They will also be advised to implement
any other general lifestyle changes suggested by the clin-
ician following the clinic consultation.
Comparisons
Men randomised to the control group will not be given
the Babystart® FertilMate™ Scrotum Cooling Patches to
wear for 90 days but will be advised to implement any
other general lifestyle changes suggested by the clinician
following the clinic consultation.
Follow-up
All participants will be reviewed in the fertility clinic
after 90 days of wearing or not wearing the scrotal cool-
ing patches and the following variables will be recorded
on the research proforma: medical history, cigarette and
alcohol use in the preceding 90 days, and body mass
index. A semen analysis will be performed according to
the standard clinic protocols for the sperm count, motil-
ity and morphology. A blood sample will be collected for
endocrine variables including testosterone, follicle stimu-
lating hormone and luteinising hormone. Serum samples
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three-dimensional ultrasound scan of the scrotum will
be performed to evaluate scrotal testicular blood flow,
volume and morphology.
Outcome measures
The primary outcome measure will be the change in
sperm concentration after 90 days in men wearing the
Babystart® FertilMate™ Scrotum Cooling Patch compared
to men not wearing the scrotal cooling patch. Secondary
outcome measures will include the change in sperm
volume, motility and morphology. Other secondary
outcome measures will include the change in endocrine
parameters (testosterone, follicle stimulating hormone
and luteinising hormone), metabolomics biomarkers,
testicular volume and blood flow as measured on three-
dimensional ultrasound. Statistical correlations between
testicular volume, blood flow and metabolomics biomar-
kers and semen parameters will also be evaluated. The
number of potentially eligible men seen at each clinic
will be noted and the proportion of these who consented
to the study and completed the study will also be evalu-
ated. Reasons for dropping out and non-compliance will
also be noted and reported.
Statistics and data-analysis
Baseline characteristics will be compared between men
wearing the scrotal patches and controls by using Chi-
squared tests for categorical variables and independent t-
test for the normally distributed continuous variables. If
the assumptions for normality are violated then non-
parametric techniques will be applied. All statistical ana-
lyses will be conducted using SPSS or other validated
statistical software and statistical significance reached
when P <0.05 (two-tailed). Furthermore, parameter esti-
mates will also be accompanied with 95% confidence
intervals. No formal power calculation was done for this
pilot study but we aim to invite sufficient eligible men to
participate such that we actually recruit 20 men into
each arm of the study (40 in total). This number was
thought to be reasonable for estimating standard devia-
tions of continuous variables and estimating recruitment
to inform a definitive trial if required. Dichotomous data
will be analysed as rates and continuous data as medians
and ranges.
Discussion
This study addresses an important but insufficiently
explored area of male fertility. The potential economic
benefits lie in the fact that the use of the scrotal cooling
patches could, alongside the implementation of other
important lifestyle changes in men with suboptimal
sperm parameters, reduce the number of men who need
expensive assisted conception. The study startedrecruiting in October 2011 and to date (November 2011)
four men have been consented and are participating in
the study. We have not encountered any operational
challenges so far.
The study was also set up as a feasibility study and
aims to evaluate factors which would be important
should a definitive study be required. These include the
recruitments rates and data for a power calculation.
However, as we do not quite know how marked the
effect of the scrotal patches will be, we decided to make
the change in sperm count after 90 days of wearing the
scrotal cooling patches compared with the control group
the primary outcome measure, because if statistically
significant differences between groups are identified, a
post hoc sample size calculation could show that the
current sample size (20 in each arm) was of sufficient
power.
There was some discussion about the need or not for
placebo patches in the control group. We decided
against this as the placebo patches could raise the scrotal
temperatures in men wearing them, resulting in a lower-
ing of the sperm parameters in the control group intro-
ducing bias.
We have also chosen to assess testicular blood flow in
this project as some studies show that this is associated
with male fertility [14]. Endocrine factors and seminal
fluid metabolomic biomarkers [15] have also previously
been evaluated and shown to be related to male fertility.
We have therefore also used the opportunity to investi-
gate whether changes in endocrine levels and serum
metabolomic profiles, which are possible surrogate mar-
kers of male fertility, occur as a result using the scrotal
cooling patches.
Assessing compliance was considered to be an import-
ant issue to address as there were no valid biological
variables identified for measuring compliance to the
scrotal cooling patches. We chose to rely on the infor-
mation provided by the participants at their follow-up
visits. However, using questionnaire interviews to meas-
ure compliance is a scientifically valid tool and has previ-
ously been used in other studies [16]. The risk of cross
contamination was considered as the patches were
commercially available on the internet. Men in the
control group could, in theory, purchase them and use
them during the study. We agreed to minimise this risk
this by reassuring men in the control group that should
the scrotal cooling patches be found to be of significant
benefit, they will be offered the scrotal patches free of
charge after the trial period.
Fertility is a complex process involving mechanical,
male, female and unknown factors. One challenge is
determining whether or not any differences or improve-
ments identified in this study could translate into
improved live birth rates, which is the primary outcome
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clinic. We do not think it will be possible to address this
issue in a study this size unless the effect size is marked,
which remains to be determined. However, data from
this study would be invaluable in planning a future trial
with live birth rates as the primary outcome of interest.
Nonetheless, we hope that this study stimulates greater
interest in the scientific community in a research area
that could potentially reduce the costs associated with
the treatment of male infertility.
Trial status
The trial is in the initial recruitment phase and has four
participants to date.
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